Resources
Show All Related Tags
Did you mean
FDA (11,279 results), Shoppers Drug Mart Ltd. (394 results), Kerr Drug Inc. (107 results), drug company (76 results), prescription drug (72 results)more...
Show Fewer Related Tags
Did you mean
FDA (11,279 results), Shoppers Drug Mart Ltd. (394 results), Kerr Drug Inc. (107 results), drug company (76 results), prescription drug (72 results), drug (63 results), Longs Drug Stores Corp. (36 results), drug testing (31 results), Discount Drug Mart Inc. (29 results), Smith's Food & Drug Centers Inc. (6 results), Glazer's Wholesale Drug Company Inc., Guardian Drug Co., Trading Co. Stores, Food & Drug, Value Drug Co.fewer...
BNET Resources
- sort by:
- Relevance
- Date
- Popularity
- Performance-Enhancing Drugs at Work: An Ethics Poll
- Is the asterisk coming to the business world? The use of performance-enhancing drugs has clogged up the sports world for the last couple of years, but steroid and human growth hormone are not the only way to get a chemical advantage. What about the brain drugs, those...
- Blog posts 2008-05-12
- Marketing Trumps Science in Vytorin Scandal
- In one of the drug industry's more revealing scandals in a while, Merck and Schering-Plough are struggling to rescue two new cholesterol drugs from evidence that they're useless at fighting heart disease and charges that the two companies deliberately sat on the bad news for roughly a year. ...
- Blog posts 2008-04-01
- Brain Steroids: Ban Or Boost?
- Drugs are bad for productivity, right? Well, maybe not. While you can probably correlate productivity increases with declines in per capita drinking, what about coffee or Diet Coke? These can act as mild stimulants. Then there's full-fledged brain steroids, say, a drug like Provigil, which...
- Blog posts 2008-03-24
- The U.K.'s NICE: A Model for the U.S.?
- The New York Times has aired another episode of its "Evidence Gap" series, and it's infuriating. This one is about the National Institute for Health and Clinical Excellence, the U.K.'s price-approval body for National Health Service drugs. The purpose of NICE is to evaluate drug efficacy and...
- Blog posts 2008-12-03
- Pharma Roundup: Sanofi in China, Wyeth and Fen-Phen, Chantix Problems, and More
- Special "While Merck Was Slashing Jobs" Edition: Sanofi-Aventis boosts R&D program in China, Wyeth still paying for Fen-Phen, Chantix blamed for 1,001 Q1 injuries, one in four biotech drugs cause dangerous side effects. by John Maas
- Blog posts 2008-10-22
- China Sky One Starts Production at New Subsidiary
- ChinaBio Today submits: China Sky One Medical CSKI announced that production has started at the Peng Lai Jin Chuang company facility. China Sky One finalized the acquisition of Jin Chuang last month, paying $7.1 million in cash and stock to gain control of the company. Jin Chuang...
- External links 2008-10-15
- Dendreon: Pro-Provenge Activists Heap Abuse on Cancer Drug’s Critics
- It's been a just a day since Dendreon announced that the interim analysis of its Provenge anti-prostate cancer candidate showed some -- but not enough -- improvement in sufferers, and already the drug's army of web activists is heaping abuse on those who suggest that possibly, just possibly, this drug...
- Blog posts 2008-10-07
- Our Favorite Drug Company Conference Call Tap Dancers
- Drug company conference calls with Wall Street are often dull or baffling -- a fast tide of numbers and facts extracted by spreadsheet jocks. But they're often the only chance we have to hear CEOs and other senior execs talking without the benefit of prepared remarks. Every once in while...
- Blog posts 2008-11-13
- Nine New Drugs for China Sky One
- ChinaBio Today submits: China Sky One Medical, Inc. CSKI has obtained the rights to nine new drugs from Shandong Medicine Research & Development Institute, paying 15 million RMB ($2.2 million). The company estimates the nine products will generate $5 million in revenue during 2009. According to China...
- External links 2008-11-13
- Behind the Byetta Crisis: Is This Drug Really All That and a Bag of (Fat-Free) Chips?
- The current big headache for Eli Lilly and Amylin is their diabetes drug Byetta, which the FDA has linked to six cases of fatal pancreatitis. The two companies, which jointly market the drug, held a conference call yesterday in which they hoped to calm nervous investors. (It...
- Blog posts 2008-08-28
- The Changing Face Of The Pharmaceutical Industry
- The influx of Canadian pharmaceuticals in recent years has shown that not every American agrees with how their representative democracy regulates drugs. A kind of patchwork class struggle has ensued, with some opposing certain kinds of drugs on everything from financial to political to religious grounds and others being the...
- White papers 2008-01-18
- It’s Good News, Bad News for Gilead’s HIV Pill
- The good news: The FDA approved Viread, Gilead’s dwindling HIV treatment, as a therapy for hepatitis B. The drug’s sales had gone down to $613 million from a peak of $783 million as newer combination drugs -- including Gilead’s own Atripla, which includes Viread -- eroded the market for standalone...
- Blog posts 2008-08-12
- Weight-Loss Drugs -- Big Pharma’s Elusive El Dorado
- With America’s obesity problem getting worse by the day, there's plenty of money to be made fighting fat with new drugs. So why do weight-loss pills keep going down in flames? by Jim Edwards
- Blog posts 2008-07-30
- Bribing Pharma to Focus on Health Disasters
- For all its rhetoric about advancing human health, the drug industry has never shown much interest in tropical diseases that kill or plague millions of people, for the very simple reason that poor nations can't pay top dollar for new drugs. That may be changing, though, thanks to a new...
- Blog posts 2008-07-17
- Doctors vs. Drug Companies: Pharma is Winning -- So Far
- Earlier this week, the WSJ noted that oncologists are getting squeezed on the cost of expensive cancer drugs. Although the story features the usual anecdotes of doctors whose practices are in debt or who are shunting patients off to hospitals for treatment in order to save money, it’s still hard...
- Blog posts 2008-07-10
- Amylin May Abandon the "Byetta" Name for Exenatide Once Weekly
- The launch of exenatide once weekly is crucial to Amylin but the company has not yet made a decision on whether it will extend the "Byetta" brand name to the new drug. by Jim Edwards
- Blog posts 2009-05-11
- China Sky One Adds Breast Lesion Drug to Product Portfolio
- ChinaBio Today submits: China Sky One Medical CSKI has bought a proprietary breast lesion drug from Harbin Medical University for 10 million RMB ($1.5 million). The drug, which China Sky One and Harbin developed jointly, has completed its Phase I trial. In the more than 10,000 patients enrolled in...
- External links 2008-10-30
- China Sky One Expands into Injected Drugs
- ChinaBio Today submits: China Sky One Medical CSKI received SFDA approval for two new products. Sodium ferulate by injection, a TCM found in the root of Angelica sinensis, is indicated for cardiovascular disease. The drug inhibits the gathering of hematoblasts and stretches blood vessels in order to protect cardiac...
- External links 2008-10-31
- Vivus Beating Arena, Orexigen In Obesity Graveyard Race
- The race to produce a blockbuster anti-obesity pill -- a contest that no company has yet won -- got interesting this week with the news, via AP, that Arena Pharmaceuticals' data showed that its contender, lorcaserin, showed only 3.6 percent more effectiveness than a placebo. The FDA wants to see...
- Blog posts 2009-03-31
- Glaxo Wellcome: Fighting Disease and Improving Health
- Intent on improving its ability to bring new drugs to market, global pharmaceutical company Glaxo Wellcome embarked on a comprehensive redesign of its clinical development processes. Glaxo Wellcome aims to be the leading global company in fighting disease and improving health. Its R&D organization spends in the region of $2...
- Case studies
- << Previous
- page 1 of 4
- Next >>
Content Types
Refining Tags
- Jim Edwards (21 results)
- Government (19 results)
- Federal Government (18 results)
- Human Resources (15 results)
- Finance (12 results)
- FDA (12 results)
- David P. Hamilton (11 results)
- Healthcare (11 results)
- Benefits (9 results)
- Patient (9 results)
- Business Operations (9 results)
- Marketing (9 results)
- Software (8 results)
- Enterprise Software (8 results)
- Health Care (8 results)
- Pharmaceutical Company (8 results)
- Vertical Industries (7 results)
- Seeking Alpha (7 results)
- Operational Accounting (6 results)
- Management (6 results)
- China (5 results)
- Strategy (5 results)
- Biotechnology (5 results)
- Marketing Research (5 results)
- Merck & Co. Inc. (4 results)
- ChinaBio Today (4 results)
- Workforce Management (4 results)
- China Sky One Medical Inc. (4 results)
- Sales Strategy (4 results)
- Sales (4 results)
- Earnings (3 results)
- Michael Fitzgerald (3 results)
- Call Transcript (3 results)
- Investment (3 results)
- Corporate Law (3 results)
- Financial Accounting (3 results)
- Drug Company (3 results)
- Performance Management (3 results)
